Upgrade to SI Premium - Free Trial

Neurocrine (NBIX) Maintained at Underperform by BMO, PT Hiked to $74, Analyst Sees Challenging Q1

February 11, 2022 4:41 PM
BMO Capital Evan David Seigerman reiterates Underperform rating on Neurocrine Bio. (NASDAQ: NBIX) but increases price target to $74.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Trader Talk

Next Articles